The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
Molecular targeted therapy with lenvatinib is commonly offered to advanced hepatocellular carcinoma (HCC) patients, although it is often interrupted by adverse effects which require a reduction in the initial dose. Thus, an alternative lenvatinib-based therapy to compensate for dose reduction is ant...
Main Authors: | Hirotetsu Takagi, Kosuke Kaji, Norihisa Nishimura, Koji Ishida, Hiroyuki Ogawa, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/3/575 |
Similar Items
-
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2020-10-01) -
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Keisuke Koroki, et al.
Published: (2021-04-01) -
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021-08-01) -
Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
by: Ai Kuwahara, et al.
Published: (2020-08-01) -
Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
by: Wei F, et al.
Published: (2021-05-01)